A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
Open Access
- 1 August 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (3), 885-887
- https://doi.org/10.1182/blood.v98.3.885
Abstract
Internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 have been found in 20% to 30% of patients with acute myeloid leukemia (AML). These mutations constitutively activate the receptor and appear to be associated with a poor prognosis. Recent evidence that this constitutive activation is leukemogenic renders this receptor a potential target for specific therapy. In this study, dose-response cytotoxic assays were performed with AG1295, a tyrosine kinase inhibitor active against FLT3, on primary blasts from patients with AML. For each patient sample, the degree of cytotoxicity induced by AG1295 was compared to the response to cytosine arabinoside (Ara C) and correlated with the presence or absence of a FLT3/ITD mutation. AG1295 was specifically cytotoxic to AML blasts harboring FLT3/ITD mutations. The results suggest that these mutations contribute to the leukemic process and that the FLT3 receptor represents a therapeutic target in AML.Keywords
This publication has 13 references indexed in Scilit:
- Leukaemia cell drug resistance and prognostic factors in AML.European Journal of Haematology, 2009
- Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemiaBlood, 2001
- Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformationLeukemia, 2000
- Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 geneLeukemia, 2000
- Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell linesOncogene, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJCI Insight, 2000
- Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the productLeukemia, 1998
- Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitroEuropean Journal of Haematology, 1998
- Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemiasBlood, 1996
- Tyrphostins. 5. Potent Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase: Structure−Activity Relationships in Quinoxalines, Quinolines, and Indole TyrphostinsJournal of Medicinal Chemistry, 1996